Lilly to Acquire Key Genomic Medicine Platforms and Prion Disease Program from Bankrupt Sangamo
Summary
Eli Lilly has entered an agreement to acquire Sangamo Therapeutics' capsid delivery, zinc finger, and modular integrase (MINT) platforms, along with the ST-506 prion disease program. This acquisition is part of Sangamo's Chapter 11 bankruptcy proceedings, where Lilly will serve as a "stalking horse" bidder. This strategic asset acquisition follows Lilly's recent FDA approval of Foundayo and a $6.3 billion acquisition of Centessa's OX2R agonist assets, indicating continued expansion of its pipeline and technological capabilities. Acquiring these genomic medicine platforms and a specific disease program enhances Lilly's R&D capabilities, potentially at a favorable valuation due to Sangamo's bankruptcy.
At the time of this announcement, LLY was trading at $1,108.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.